Skip to main content
padlock icon - secure page this page is secure

Novel Classes of Antibacterial Drugs in Clinical Development, a Hope in a Post-antibiotic Era

Buy Article:

$68.00 + tax (Refund Policy)

Bacterial resistance is a growing problem worldwide and is estimated that deaths by infectious diseases associated with resistant pathogens will generate 10 million deaths per year in 2050. This problem becomes more serious due to the low level of research and development of new drugs, which has fallen drastically in the last 40 years. For example, in the last decade of a total of 293 new drugs approved by the FDA, only 9 corresponded to antimicrobial drugs and none constituted a new structural class. The majority of the molecules in the clinical phase II or III, coming from modifications of drugs in clinical use, this strategy makes easier the bacterial susceptibility to generate resistance through the mechanisms expressed for their drug predecessors.

Under this scenario, it is urgent to generate the most novel strategies for the development of antibacterial compounds with new targets or mechanism of action, without a structural relationship with the antibiotic drugs predecessors. Under this look, the present review addresses the development of the latest antibacterial drugs in clinical phases II and III, analyzing the design strategies by which these new molecules were obtained and the structure-activity relationship of these new families of antibiotics, in order to define the state of the vanguard antibacterial drugs in the post-antibiotic era.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Antibacterial agents; Antibiotic Development; Antibiotic resistance; Clinical development; New drugs approvals; New mechanism of action

Document Type: Review Article

Publication date: May 1, 2018

This article was made available online on August 28, 2018 as a Fast Track article with title: "Novel Classes of Antibacterial Drugs in Clinical Development, a Hope in a Post-antibiotic Era".

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more